The firm is one of several groups taking a machine learning approach, which it said will enable lower-cost, faster, and more complete proteomic analyses.
The company is working with German informatics firm MSAID to incorporate deep learning into mass spec analysis and with Biognosys on tools for quantitative work.
The startup aims to develop a low-cost, high-throughput proteomics platform that combines biochemistry with computer science and information technology.
The company uses a combination of transcriptomic and proteomic data combined with machine-learning analysis to identify immune profiles linked to disease.
The study also found that certain genes may influence multiple complex traits, while others only affect one phenotype, making them worthwhile therapeutic targets.
The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.
Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics.
